Shares of Diploma PLC (LON:DPLM – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 3,627.05 ($46.01) and traded as high as GBX 4,138 ($52.49). Diploma shares last traded at GBX 4,098 ($51.99), with a volume of 175,608 shares traded.
Analyst Upgrades and Downgrades
DPLM has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 4,500 ($57.08) price target on shares of Diploma in a report on Tuesday, May 7th. Berenberg Bank upped their price objective on Diploma from GBX 4,400 ($55.82) to GBX 4,700 ($59.62) and gave the company a “buy” rating in a research note on Monday, May 13th. Shore Capital reiterated a “buy” rating on shares of Diploma in a research report on Monday, May 13th. Finally, Barclays reaffirmed an “overweight” rating and set a GBX 4,050 ($51.38) price target on shares of Diploma in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 3,950 ($50.11).
View Our Latest Report on DPLM
Diploma Trading Up 1.2 %
Diploma Cuts Dividend
The firm also recently announced a dividend, which was paid on Friday, June 7th. Investors of record on Thursday, May 23rd were issued a dividend of GBX 17.30 ($0.22) per share. This represents a dividend yield of 0.44%. The ex-dividend date was Thursday, May 23rd. Diploma’s payout ratio is presently 6,705.88%.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Further Reading
- Five stocks we like better than Diploma
- How to Most Effectively Use the MarketBeat Earnings Screener
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- What Are Dividend Champions? How to Invest in the Champions
- Progress Software Stock Back in the Green After Beating Forecasts
- Why Invest in High-Yield Dividend Stocks?
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.